Ticagrelor CAS# 274693-27-5 替卡格雷

Ticagrelor, also known as AZD-6140 and AR-C 126532XX, is a platelet aggregation inhibitor produced by AstraZeneca. The drug was approved in 2011. Ticagrelor is an antagonist of the P2Y12 receptor. Like the thienopyridines prasugrel, clopidogrel and ticlopidine, ticagrelor blocks adenosine diphosphate (ADP) receptors of subtype P2Y12. In contrast to the other antiplatelet drugs, ticagrelor has a binding site different from ADP, making it an allosteric antagonist, and the blockage is reversible. Moreover, the drug does not need hepatic activation, which might work better for patients with genetic variants regarding the enzyme CYP2C19.